The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
Arafath K Najumudeen,Fatih Ceteci,Sigrid K Fey,Gregory Hamm,Rory T Steven,Holly Hall,Chelsea J Nikula,Alex Dexter,Teresa Murta,Alan M Race,David Sumpton,Nikola Vlahov,David M Gay,John R P Knight,Rene Jackstadt,Joshua D G Leach,Rachel A Ridgway,Emma R Johnson,Colin Nixon,Ann Hedley,Kathryn Gilroy,William Clark,Sudhir B Malla,Philip D Dunne,Giovanny Rodriguez-Blanco,Susan E Critchlow,Agata Mrowinska,Gaurav Malviya,Dmitry Solovyev,Gavin Brown,David Y Lewis,Gillian M Mackay,Douglas Strathdee,Saverio Tardito,Eyal Gottlieb,CRUK Rosetta Grand Challenge Consortium,Zoltan Takats,Simon T Barry,Richard J A Goodwin,Josephine Bunch,Martin Bushell,Andrew D Campbell,Owen J Sansom,Andrew Campbell,Arafath Najumudeen,Ian Gilmore,Greg McMahon,Paul Grant,Bin Yan,Adam J Taylor,Efstathios Elia,Spencer Thomas,Catherine Munteanu,Ala Al-Afeef,Amy Burton,Jean-Luc Vorng,Xavier Loizeau,Weiwei Zhou,Ammar Nasif,Ariadna Gonzalez,Hanifa Koquna,Martin Metodiev,Melina Kyriazi,Junting Zhang,Lucas Zeiger,Johan Vande-Voorde,Jennifer Morton,Dmitry Soloviev,Vincen Wu,Yuchen Xiang,Daniel McGill,Stefania Maneta-Stravrakaki,Jaynisha Mistry,Emine Kazanc,Mariia Yuneva,Yulia Panina,Chandan Seth Nanda,Peter Kreuzaler,Avinash Ghanate,Stephanie Ling,Jack Richings,Kevin Brindle,Anastasia Tsyben,George Poulogiannis,Amit Gupta,Aurelien Tripp,Evi Karali,Nikolaos Koundouros,Thanasis Tsalikis,John Marshall,Magali Garrett,Harry Hall
DOI: https://doi.org/10.1038/s41588-020-00753-3
Abstract:Oncogenic KRAS mutations and inactivation of the APC tumor suppressor co-occur in colorectal cancer (CRC). Despite efforts to target mutant KRAS directly, most therapeutic approaches focus on downstream pathways, albeit with limited efficacy. Moreover, mutant KRAS alters the basal metabolism of cancer cells, increasing glutamine utilization to support proliferation. We show that concomitant mutation of Apc and Kras in the mouse intestinal epithelium profoundly rewires metabolism, increasing glutamine consumption. Furthermore, SLC7A5, a glutamine antiporter, is critical for colorectal tumorigenesis in models of both early- and late-stage metastatic disease. Mechanistically, SLC7A5 maintains intracellular amino acid levels following KRAS activation through transcriptional and metabolic reprogramming. This supports the increased demand for bulk protein synthesis that underpins the enhanced proliferation of KRAS-mutant cells. Moreover, targeting protein synthesis, via inhibition of the mTORC1 regulator, together with Slc7a5 deletion abrogates the growth of established Kras-mutant tumors. Together, these data suggest SLC7A5 as an attractive target for therapy-resistant KRAS-mutant CRC.